Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Klinisk randomisert fase 2-studie av AP31969 versus placebo for rytmekontroll av atrieflimmer (END-AF-1)

28. september 2026 oppdatert av: Acesion Pharma

A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

The key goal of this clinical trial is to assess the effectiveness of different doses of AP31969 in lowering Atrial Fibrillation (AF) burden and its safety.

Participants will be randomly assigned to one of the following groups:

  • AP31969 at 100 mg, 200 mg, or 350 mg doses
  • AP31969 500 mg (not included at the trial start)
  • Placebo (inactive treatment and has no active properties). The placebo group serves as the comparator for AP31969. All treatments are given orally, twice daily.

The trial includes 3 periods: screening (up to 4 weeks), treatment (12 weeks), and follow-up (30 days). The duration of the trial for a participant is approximately 20 weeks.

Participants will receive an implantable loop recorder and undergo assessments during the visits at specific times, for example blood and urine analyses, and electrocardiogram.

Studietype

Intervensjonell

Registrering (Antatt)

200

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • PD
      • Plovdiv, PD, Bulgaria, 4002
        • Rekruttering
        • UMHAT "Sveti Georgi" EAD, Department of Invasive Cardiology
    • SOF
      • Sofia, SOF, Bulgaria, 1000
        • Rekruttering
        • Acibadem City Clinic, Cardiology Department
      • Sofia, SOF, Bulgaria, 1365
        • Tilbaketrukket
        • MHAT National Cardiology Hospital EAD, Cardiology Department
      • Sofia, SOF, Bulgaria, 1431
        • Rekruttering
        • Aleksandrovska University Hospital, Clinic of Cardiology
    • VAR
      • Varna, VAR, Bulgaria, 9000
        • Rekruttering
        • SHATC Cardiolife, Invasive Cardiology
      • Varna, VAR, Bulgaria, 9020
        • Rekruttering
        • Medical Center Nova Clinic
      • Hellerup, Danmark, 2730
        • Rekruttering
        • University Hospital Herlev and Gentofte Department of Cardiology
      • Viborg, Danmark, 8800
        • Rekruttering
        • Viborg Hospital, Department of Cardiology
      • Milan, Italia, 20162
        • Rekruttering
        • ASST Grande Ospedale Metropolitano Niguarda Cardiology 3 - Electrophysiology "De Gasperis" Cardio Center
      • Milan, Italia, 20122
        • Har ikke rekruttert ennå
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Cardio - Thoracic- Vascular Diseases,
      • Modena, Italia, 30174
        • Rekruttering
        • University of Modena and Reggio Emilia, Policlinico di Modena, Cardiology Department
    • BO
      • Bologna, BO, Italia, 40138
        • Rekruttering
        • Policlinico Sant'Orsola Cardiology Department
    • FE
      • Cona, FE, Italia, 444124
        • Rekruttering
        • Arcispedale Sant'Anna, Cardiology Department
    • VE
      • Mestre, VE, Italia, 30174
        • Rekruttering
        • Dell'Angelo Hospital, Cardiology Department
      • Arnhem, Nederland, 6815 AD
        • Rekruttering
        • Rijnstate Ziekenhuis, Cardiology Department
      • Deventer, Nederland, 7416 SE
        • Rekruttering
        • Deventer Ziekenhuis, Cardiology Department
      • Groningen, Nederland, 9728 NT
        • Rekruttering
        • Martini Hospital Groningen, Cardiology Department
      • Haarlem, Nederland, 2035 RC
        • Rekruttering
        • Spaarne Gasthuis, Cardiology Department
      • Leeuwarden, Nederland, 8934 AD
        • Tilbaketrukket
        • Frisius MC Leeuwarden, Hart- en Vaatcentrum
      • Maastricht, Nederland, 6229 HX
        • Aktiv, ikke rekrutterende
        • Maastricht University Medical Center, Cardiology Department
      • The Hague, Nederland, 2545 AA
        • Rekruttering
        • HagaZiekenhuis, Cardiology/Electrophysiology Unit
      • Tiel, Nederland, 4002 WP
        • Rekruttering
        • Rivierenland Hospital, Cardiology Department
      • Veldhoven, Nederland, 5504 DB
        • Rekruttering
        • Máxima Medisch Centrum, Cardiology Department
      • Bydgoszcz, Polen, 85-231
        • Rekruttering
        • Centrum Medyczne KERmed Cardiology Department
      • Chrzanów, Polen, 85-231
        • Rekruttering
        • Małopolskie Centrum Sercowo-Naczyniowe PAKS Oddział Intensywnej Opieki Kardiologicznej
      • Dąbrowa Górnicza, Polen, 41-300
        • Rekruttering
        • Polsko-Amerykańskie Kliniki Serca III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
      • Katowice, Polen, 40-635
        • Har ikke rekruttert ennå
        • Upper-Silesian Medical Center 2nd Department of Cardiology
      • Katowice, Polen, 40-635
        • Har ikke rekruttert ennå
        • Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach
      • Szczecin, Polen, 70-419
        • Rekruttering
        • One Day Med Sp. z o.o. Clinical Trials Department
      • Tychy, Polen, 43-100
        • Rekruttering
        • Polsko-Amerykańskie Kliniki Serca X Oddział Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji w Tychach im
      • Belgrade, Serbia
        • Rekruttering
        • University Clinical Centre of Serbia Department for Intensive Care in Arrhythmology
      • Belgrade, Serbia
        • Rekruttering
        • Institute for Cardiovascular Disease "Dedinje" Department for Electrophysiology
      • Kamenitz, Serbia
        • Rekruttering
        • Institute for Cardiovascular Diseases Vojvodina Department of Interventional Electrophysiology
      • Kragujevac, Serbia
        • Rekruttering
        • University Clinical Center Kragujevac Clinic of Cardiology (Depar. Electrophysiology)
      • Niš, Serbia
        • Rekruttering
        • University Clinical Center Nis Clinic for Cardiovascular Diseases Bulevar
      • Užice, Serbia, 33100
        • Rekruttering
        • Health Center Uzice Cardiology Department
      • Coburg, Tyskland, 96450
        • Rekruttering
        • Sana Kliniken Oberfranken, Klinikum Coburg Kardiologie und Innere Medizin
      • Frankfurt, Tyskland, 60590
        • Rekruttering
        • Universitätsklinikum Frankfurt Medizinische Klinik III - Kardiologie, Angiologie, Hämostaseologie, Nephrologie
      • Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitaets Klinikum Hamburg-Eppendorf (UKE Hamburg), Kardiologie
      • Budapest, Ungarn, 1122
        • Rekruttering
        • Semmelweis Egyetem Városmajori Sziv- és Érsebészeti Klinika
      • Budapest, Ungarn, 1023
        • Rekruttering
        • Budai Irgalmasrendi Kórház
      • Sopron, Ungarn, 9400
        • Tilbaketrukket
        • Soproni Gyógyközpont Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet
      • Szeged, Ungarn, 6725
        • Rekruttering
        • Szent-Györgyi Albert Klinikai Központ, Belgyógyászati Klinika
      • Szolnok, Ungarn, 5000
        • Rekruttering
        • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet
      • Zalaegerszeg, Ungarn, 8900
        • Rekruttering
        • Belvárosi Egészségház, Platán Magánklinika
    • Hungary
      • Pécs, Hungary, Ungarn, 7622
        • Har ikke rekruttert ennå
        • Pécsi Tudományegyetem Szivgyógyászati Klinika (Cardiology Clinic, University of Pecs)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Willing and able to provide written informed consent.

  • Age 18 or older.

  • ECG documented diagnosis of paroxysmal or persistent AF.

  • AF history at screening indicating an expected AF burden of 1-90%, i.e., at least 1 self-terminating AF episode within 4 months prior to the screening visit.

  • AF burden of ≥ 1% and ≤ 90% assessed with an ECG patch device during the screening period prior to the randomisation visit.

  • Investigator and participant agreement to avoid non-trial related rhythm control intervention for the duration of the trial, including:

    • Antiarrhythmic drug class I and/or III (including amiodarone)
    • Electrical or pharmacological cardioversion
    • AF ablation procedure
  • Willing to have a loop recorder implanted.

Exclusion Criteria:

  • Prior AF ablation procedure other than pulmonary vein isolation (PVI) only.
  • Any of the following events within 4 weeks prior to the screening visit: Myocardial infarction, Unstable angina pectoris, Stroke or transient, ischaemic attack, Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG), Peripheral revascularisation procedure.
  • Cardiac pacing device e.g. pacemaker and cardiac resynchronization therapy device with atrial or ventricular pacing for > 5% of the time or existing implantable loop recorder.
  • Heart failure, New York Heart Association class III (3) or IV (4).
  • Left ventricular ejection fraction < 40% based on imaging (e.g. echocardiography) performed within 6 months prior to or during the screening visit.
  • Clinically significant valvular heart disease, including severe aortic stenosis, severe mitral regurgitation and/or severe mitral stenosis, in the opinion of the investigator.
  • QTc (Fridericia, QTcF) interval > 450 ms for males and > 470 ms for females at screening.
  • eGFR <60 mL/min /1.73 m² based on creatine and CKD-EPI formula
  • Use of antiarrhythmic drug class I and/or III within 7 days or, for amiodarone, within 3 months prior to the screening visit.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: AP31969 100 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentell: AP31969 200 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentell: AP31969 350 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentell: AP31969 500 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Placebo komparator: Placebo

Tablets, Twice daily, 12 Weeks

Tablets, oral, Twice daily.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Atrial fibrillation burden
Tidsramme: From week 2 to week 12

Measured through implantable loop recorder. Calculated as the amount of time with AF relative to the amount of time the participant is under observation (expressed as a %).

From week 2 to week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of atrial fibrillation episodes
Tidsramme: From week 2 to week 12

Measured through implantable loop recorder.

From week 2 to week 12
Change from baseline in Atrial Fibrillation Effect on Quality-of-Life
Tidsramme: Week 12

Patient reported outcome. Reporting on a scale of 1 to 7, where 7 is the worse outcome.

Week 12
Number of ventricular tachycardia episodes > 30 seconds of duration
Tidsramme: From week 0 to week 12

Measured through implantable loop recorder.

From week 0 to week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. oktober 2025

Primær fullføring (Antatt)

1. mai 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

25. november 2025

Først innsendt som oppfylte QC-kriteriene

25. november 2025

Først lagt ut (Faktiske)

5. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • AP31969-M201
  • 2025-521377-14-00 (Ctis)
  • 2025 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified external researchers may request access to anonymized data and needed trial documentation. Requests are evaluated on the basis of scientific merit. Any use of and access to the data must respect the privacy of the participants and will only be provided if applicable laws and regulations allow this.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere